Exelixis, Inc. (NASDAQ:EXEL) – Investment analysts at William Blair issued their Q1 2018 earnings per share (EPS) estimates for shares of Exelixis in a report released on Wednesday. William Blair analyst A. Hsieh forecasts that the biotechnology company will post earnings of $0.09 per share for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Exelixis’ Q2 2018 earnings at $0.10 EPS, Q3 2018 earnings at $0.15 EPS, Q4 2018 earnings at $0.20 EPS and FY2018 earnings at $0.55 EPS.

EXEL has been the subject of several other research reports. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $29.00 price target on shares of Exelixis in a report on Thursday. Cann reaffirmed a “hold” rating on shares of Exelixis in a report on Wednesday, April 19th. Zacks Investment Research cut Exelixis from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 28th. Deutsche Bank AG cut Exelixis from a “buy” rating to a “hold” rating and increased their price target for the company from $26.00 to $29.00 in a report on Thursday. Finally, SunTrust Banks, Inc. began coverage on Exelixis in a report on Thursday, July 13th. They issued a “buy” rating and a $33.00 price target for the company. Five equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $25.57.

ILLEGAL ACTIVITY WARNING: This story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/08/07/exelixis-inc-forecasted-to-post-q1-2018-earnings-of-0-09-per-share-nasdaqexel.html.

Exelixis (NASDAQ:EXEL) opened at 26.66 on Monday. Exelixis has a one year low of $9.00 and a one year high of $28.45. The stock has a market cap of $7.84 billion, a PE ratio of 138.85 and a beta of 1.89. The stock has a 50 day moving average price of $24.89 and a 200-day moving average price of $21.88.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 EPS for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.02. The firm had revenue of $99.01 million during the quarter, compared to analysts’ expectations of $85.27 million. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. The company’s quarterly revenue was up 173.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.15) EPS.

In other Exelixis news, CEO Michael Morrissey sold 100,000 shares of the firm’s stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $21.69, for a total transaction of $2,169,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Patrick J. Haley sold 5,000 shares of the firm’s stock in a transaction on Tuesday, May 30th. The stock was sold at an average price of $18.46, for a total value of $92,300.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 349,288 shares of company stock valued at $7,594,312. 5.10% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the company. Legal & General Group Plc boosted its stake in Exelixis by 1.3% in the first quarter. Legal & General Group Plc now owns 84,763 shares of the biotechnology company’s stock valued at $1,834,000 after buying an additional 1,078 shares during the period. Aperio Group LLC boosted its stake in Exelixis by 2.7% in the second quarter. Aperio Group LLC now owns 58,345 shares of the biotechnology company’s stock valued at $1,437,000 after buying an additional 1,514 shares during the period. Teacher Retirement System of Texas boosted its stake in Exelixis by 7.0% in the second quarter. Teacher Retirement System of Texas now owns 23,251 shares of the biotechnology company’s stock valued at $573,000 after buying an additional 1,517 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Exelixis by 14.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,751 shares of the biotechnology company’s stock valued at $320,000 after buying an additional 1,838 shares during the period. Finally, Meeder Asset Management Inc. boosted its stake in Exelixis by 26.6% in the second quarter. Meeder Asset Management Inc. now owns 9,957 shares of the biotechnology company’s stock valued at $245,000 after buying an additional 2,091 shares during the period. 80.19% of the stock is owned by institutional investors.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Earnings History and Estimates for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.